Genesis Therapeutics
Principal Scientist, Computational Biology
Job Description
What You Will Do (Key Responsibilities)
- Successfully perform biological experiments with minimal input from supervisor to interrogate target function.
- Execute MOA studies and develop assays to drive SAR for a diverse set of targets across multiple projects.
- Independently analyze experimental data, interpret results, and lead troubleshooting efforts when necessary.
- Present work to supervisor, lab and/or project meeting on regular basis.
- Document experiments in electronic lab notebook in an accurate and timely manner.
What you’ll bring
- M.S. in Biology/Molecular Biology/Biochemistry or related discipline with 3-4+ years industry experience
- Or Ph.D. in Cancer Biology/Immunology or related discipline with 0-1+ years industry experience
- Experience with tissue culture, cell-based assays, plate-based readouts and molecular biology/biochemistry techniques such as cloning, ELISA, qPCR, and western blot is required.
- Familiarity with genetic manipulation techniques such as siRNA, shRNA, CRISPR, knockin/overexpression is preferred.
- Prior experience in discovery, hit ID, validation, and characterization in oncology/immunology is a plus.
- Outstanding written and oral communication skills, enthusiasm, integrity, self-motivation, strong interpersonal skills, and attention to detail are required.
What we offer
- Competitive Pay
- Stock Option Eligibility
- 401(k) Plan
- Open PTO Policy
- Paid Company Holidays
- Free lunch and snacks at our offices
- Health Care Plan, including Medical, Dental, and Vision, fully covered for the employees
Genesis Therapeutics is a pioneering AI Biotech company focusing on the discovery of novel drugs using unique approaches to both undrugged and underdeveloped targets with the goal of providing new treatments for patients with severe diseases. Genesis has raised over $280M in funding from top technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA’s VC arm), BlackRock, and Menlo Ventures. In addition, Genesis has announced two AI platform collaborations across a range of therapeutic areas with Genentech and h Eli Lilly, the latter of which entailed a $20M upfront payment with a $670M total deal size. We’ve also been featured in Forbes 30u30 and in Forbes AI 50. Genesis originated in graph machine learning research in Vijay Pande’s lab at Stanford, when it was joined by legendary drug hunters and biotech entrepreneurs (including Dr. Leonard Bell, founder and CEO of Alexion Pharmaceuticals, acquired by Astra Zeneca for $39Bn; and Peppi Prasit, storied chemist from Merck known for Vioxx, Arcoxia, Singulair, who then went on to found Amira Pharmaceuticals, acquired by BMS, and Inception Sciences). The company is making strong progress in expanding the domain of our AI technology with the advance of our pipeline of best-in-class and first-in-class programs, both internal targets and those in partnership with Genentech and Lilly.
Genesis Therapeutics is unifying AI and biotech to discover novel and breakthrough treatments for patients with severe and devastating conditions. Genesis was founded on groundbreaking molecular ML research and since has established itself as the industry leader in AI for small molecule drug discovery. Our team of accomplished biotech leaders and expert drug hunters joins forces with deep learning researchers and software engineers who are pioneering predictive and generative AI technologies for molecules.
Our team has created the industry’s most advanced molecular AI platform called GEMS (Genesis Exploration of Molecular Space), to accelerate and optimize small molecule drug discovery and to enable the discovery of novel first-in-class and best-in-class small molecule drugs for challenging and/or undruggable targets.
The company has leveraged GEMS to build an internal pipeline with multiple programs against high-value targets, including data-poor and canonically undruggable targets where GEMS is uniquely advantaged. In addition, Genesis has two AI platform collaborations across a range of therapeutic areas: Eli Lilly (signed in 2022, with a $20M upfront payment and a $670M total deal size), and Genentech (signed in 2020).We raised a $200M series B in August 2023, and have raised over $280M in funding from top technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA’s VC arm), BlackRock, and Menlo Ventures.
Genesis is headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego. We are proud to be an inclusive workplace and an Equal Opportunity Employer.
Finding the best talent is our top priority at Genesis Therapeutics. If you are interested in potential partnership on recruitment, please reach out to [email protected].
